Bicara Therapeutics Quarterly Balance Sheet
NASDAQ: BCAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bicara Therapeutics financial position
As of Jun 30, 2026, Bicara Therapeutics reported total assets of $512.2 million, up 12.9% from a year earlier against total liabilities of $43.5 million. Shareholders' equity stood at $468.8 million, or 91.5% of assets. The company held $96.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 11.59, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Bicara Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 96.60M | 323.46M | 96.69M | 171.67M | 436.61M | 462.06M | 489.71M | 520.76M | 203.85M | 216.05M | 230.44M | 44.21M |
| Short-Term Investments | 400.66M | 216.29M | 318.12M | 118.49M | — | — | 0 | — | — | — | — | — |
| Total Current Assets | 503.82M | 544.91M | 422.05M | 297.37M | 444.39M | 470.75M | 502.53M | 521.51M | — | — | 231.07M | — |
| Property, Plant & Equipment | 362.00K | 346.00K | 330.00K | 135.00K | 117.00K | 136.00K | 155.00K | 130.00K | — | — | 202.00K | — |
| Long-Term Investments | — | — | — | 117.42M | — | — | 0 | — | — | — | — | — |
| Total Assets | 512.24M | 553.60M | 430.99M | 424.69M | 453.59M | 478.08M | 510.00M | 524.17M | — | — | 233.98M | — |
| Total Current Liabilities | 43.48M | 39.34M | 28.95M | 21.03M | 17.23M | 19.12M | 17.99M | 14.48M | — | — | 15.09M | — |
| Total Liabilities | 43.48M | 39.64M | 29.54M | 21.91M | 18.39M | 19.12M | 18.12M | 14.62M | — | — | 15.47M | — |
| Shareholders' Equity | 468.77M | 513.96M | 401.45M | 402.78M | 435.20M | 458.96M | 491.88M | 509.56M | -174.78M | -160.08M | -148.77M | -137.11M |
| Retained Earnings | -470.61M | -415.18M | -358.97M | -321.58M | -285.25M | -257.86M | -221.02M | -200.06M | — | — | -153.02M | — |
| Net Cash (Debt) | 497.26M | 539.75M | 414.80M | 290.17M | 436.61M | 462.06M | 489.71M | 520.76M | 203.85M | 216.05M | 230.44M | 44.21M |
| Shares Outstanding | 65.93M | 65.55M | 56.60M | 54.61M | 54.56M | 54.53M | 54.44M | 54.41M | — | — | 640.39K | — |
This table shows 12 quarterly periods of Bicara Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow BCAX's reporting calendar. What is a balance sheet?